VC  Tekla Capital Management

http://www.teklacap.com/





     Office Locations:

100 Federal Street, 19th Floor
Boston, MA 02110

 

Stages:

  • Growth


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Founded in 1986, the Tekla Capital Management is an employee owned investment manager. Tekla is a registered investment advisor for four closed-end funds, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. The Funds predominately invest in the securities of public and private healthcare companies. Tekla Healthcare Investors (HQH) is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQL. Tekla Healthcare Opportunities Fund (THQ) is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THQ. Tekla World Healthcare Fund (THW) is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THW.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Alan Kwan MBA, PhD Senior Analyst, Research
    Chris Abbott Senior Analyst, Research
    Christian Richard MS, MBA Senior Vice President, Research
    Daniel R. Omstead PhD President and CEO
    Jason C. Akus MBA, MD Senior Vice President, Research

     

    Portfolio companies include:


      Alexion Pharmaceuticals


      Allergan


      BioClin Therapeutics
        web link


      Biogen


      BioMarin Pharmaceutical
        web link


      CardioKinetix
        web link


      Celgene
        web link


      Gilead Sciences


      Illumina
        web link


      IlluminOss Medical
        web link


      Incyte


      Ovid Therapeutics
        web link


      Regeneron Pharmaceuticals


      Veniti
        web link


      Vertex Pharmaceuticals


     

    Recent News: